Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm to Present at Upcoming Health Care Investor Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2020 Financial Results
Third   Q uarter T otal R evenue I n creased 50   P ercent to $ 39 .9   M illion Third Q uarter P roduct and Service R evenue I ncreased 34   P ercent to   $35 . 3 M illion   D riven by COVID-19 T esting GAAP N et L oss in the T hird Q uarter Was $6.0   M illion ; Non-GAAP N et I ncome W as $2.5  
View HTML
Toggle Summary Fluidigm and Healthvana Partner to Offer COVID-19 Test Results Delivery through Innovative Digital Platform
Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm Mass Cytometry Technologies, Including CyTOF, Imaging Mass Cytometry and Maxpar Direct, Utilized in More than 100 National Clinical Trials
25 Trials Utilizing Mass Cytometry Initiated in 2020 SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass
View HTML
Toggle Summary Dante Labs Launching COVID-19 Testing in Europe Utilizing Fluidigm Pathogen Detection Kit on Biomark HD Platform
Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution Fluidigm   Powered Testing Service to be Rolled Out in Seven European Countries SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative
View HTML
Toggle Summary Fluidigm to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities
Fluidigm COVID-19 Campus Safeguard Program Improves Availability of Non i nvasive, Saliva-Based SARS-CoV-2 Test s   for Higher Education   Institutions High-Throughput , Integrated Testing Platform and Reliable Supply Chain SOUTH SAN FRANCISCO, Calif. , Oct.
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2020 financial results on Thursday,
View HTML
Toggle Summary Fluidigm Joins Global Consortium of Cancer Prevention Experts
CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
Regional CLIA-Certified Labs among Growing Number of Customers Expanding SARS-CoV-2 Testing with Fluidigm Technology SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit
Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based Discoveries in Infectious Disease, Immunology and the Tumor Microenvironment SOUTH SAN FRANCISCO, Calif.
View HTML